Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Ancilia Biosciences
AddedFeb 16, 2024
UpdatedJun 18, 2026
Ancilia Biosciences

Ancilia Biosciences

Ancilia Biosciences, a NYC-based software company, develops bacterial therapies for chronic diseases.

HQ
New York City, NY, US
Founded
2019
Overview
Compare
Fundraising
Employees
Website

Ancilia Biosciences, founded in New York City, focuses on developing engineered bacterial therapies to treat diseases linked to the microbiome. Their core mission is to harness the natural power of CRISPR technology through their proprietary CoVE™ platform to address chronic diseases in immunology and oncology. By targeting the viral components of the microbiome, Ancilia aims to transform the treatment landscape for a variety of health conditions.

Notable affiliated individuals include experts in microbiology and biotechnology, though specific names are not provided. The company has achieved significant milestones in developing novel bacterial therapies, positioning itself as a pioneer in microbiome-related treatments. Ancilia's impact lies in its innovative approach to leveraging beneficial bacteria for therapeutic purposes, potentially revolutionizing how chronic diseases are managed.

Ancilia Biosciences - Similar Companies

Ancora Biotech logo

Ancora Biotech

ancorabiotech.com

Nexilico logo

Nexilico

nexilico.com

Nextbiotics logo

Nextbiotics

next-biotics.com

Federation Bio logo

Federation Bio

federation.bio

Petri Bio logo

Petri Bio

petribio.com

SciBac logo

SciBac

scibac.com

Selva logo

Selva

Locus Biosciences logo

Locus Biosciences

locus-bio.com

Analytica Biosciences logo

Analytica Biosciences

Vulcan Biologics logo

Vulcan Biologics

MarvelBiome logo

MarvelBiome

marvelbiome.com

Vedanta Biosciences logo

Vedanta Biosciences

vedantabio.com

Cryptyx Bioscience logo

Cryptyx Bioscience

Anvesana logo

Anvesana

Scioto Biosciences logo

Scioto Biosciences

Ancilia Biosciences - Quick Facts

Who are Ancilia Biosciences' competitors?

Companies similar to Ancilia Biosciences include Ancora Biotech, Nexilico, Nextbiotics and Federation Bio.

When was Ancilia Biosciences founded?

Ancilia Biosciences was founded in 2019.

Where is Ancilia Biosciences' headquarters located?

Ancilia Biosciences' headquarters is located in New York City, NY, US.

When was Ancilia Biosciences' last funding round?

Ancilia Biosciences' most recent funding round was for $1M (USD) in May 2023.

How much has Ancilia Biosciences raised to-date?

As of May 4, 2023, Ancilia Biosciences has raised a total of $1M (USD).

How many employees does Ancilia Biosciences have?

Ancilia Biosciences has 6 employees as of Feb 5, 2024.

Ancilia Biosciences - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Bacterial Therapies
Tags
  • Biotech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software